Baxalta Inc

Baxalta — BAML Global Healthcare Conference 2015

19 slides from Baxalta's conference presentation, Sep 17, 2015

  1. Slide 1: The next step in our journey

    Jeff Poulton CFO The next step in our journey BAML Global Healthcare Conference, 2015 September 17, 2015

  2. Slide 2: Forward-looking statements

    Statements included in this announcement that are not historical facts, including without limitation statements concerning our 10x20 ambitions and targets, our proposed combination with Baxalta Incorporated (“Baxalta”), and the timing and benefits thereof, including our 20x20 ambition that targets $

  3. Slide 3: Cautionary statement and additional information

    All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the exte

  4. Slide 4: Our continuous transformation 2013-2015

    Our continuous transformation 2013-2015 Becoming OneShire Step-change in performance Effective and efficient organization Set basis for long-term growth Investing to create further long-term value 2013 2014 2015 2016 2017 2018 2019 2020+ 2014-2020+ Building a leading global biotech company Creating

  5. Slide 5: Why focus on rare diseases?

    Why focus on rare diseases? Large opportunity for innovation Huge medical burden for patients and HC systems Over 7,000 diseases, of which only 5% have treatments Increasing share of regulatory approvals in US, EU and Japan Often accelerated development due to priority review and phase-skipping Life

  6. Slide 6: Rare Diseases require unique capabilities – and ours are industry-leading

    Rare Diseases require unique capabilities – and ours are industry-leading Commercial R&D Manufacturing Many un- or misdiagnosed patients Complex disease management Significant persistence and compliance challenges Challenging trial recruitment due to small populations Complex ethical questions – pla

  7. Slide 7: Q2 2015: Progress towards becoming a leading global biotechnology company

    Q2 2015: Progress towards becoming a leading global biotechnology company Strong US launch for NATPARA in HPT Continued strong growth for VYVANSE post BED launch GATTEX performing well; implementation of enhanced commercial plans GROWTH Double digit CER(1) product sales growth excluding INTUNIV Phas

  8. Slide 8: Delivering double digit core product sales growth while investing for the future

    Delivering double digit core product sales(1) growth while investing for the future Core product sales excluding INTUNIV growing 12% on a constant exchange rate basis(2)(4) Continuing to make significant investment in expected future growth drivers: VYVANSE BED, GATTEX/REVESTIVE and NATPARA H1 Non G

  9. Slide 9: Positive momentum in VYVANSE Rx trends continues post BED approval

    GROWTH Since launch of VYVANSE for BED in Q1, we have seen a steady increase in our above market performance resulting in YoY share growth The ADHD “summer dip” has not been as steep as previous years Executing in the back-to-school season while maintaining our adult momentum Source: weekly IMS data

  10. Slide 10: Leveraging Shire's capabilities to grow GATTEX

    Leveraging Shire’s capabilities to grow GATTEX New field based patient support role (Onboarding & Access Specialist/OAS) to aid with initiation of therapy OAS also supports early experience with GATTEX Legacy NPS GATTEX sales team dedicated to converting patient leads Over 500 patients on therapy in

  11. Slide 11: Strong start for Natpara in the US

    Strong start for Natpara in the US NATPARA launched in the US April 1, 2015 NATPAR submitted in EU December 2014; filing on track with estimated approval in Q1 2016 Positive response from Endocrinologists to NATPARA Over 70% of target US physicians REMS(1) trained (~1,900) as at end of June 2015 App

  12. Slide 12: Late stage pipeline poised to deliver

    Late stage pipeline poised to deliver Preclinical Phase 1 Phase 2 Phase 3 Registration TH / GCH1 GenePod Parkinson’s Subset 26 Research Programs SHP608 Dystrophic E.Bullosa SHP631 Hunter Syndrome SHP624 Heme B Gene Edit SHP623 (rC1-INH) HAE prophylaxis SHP611 MLD (Ph 1/2) SHP616 (CINRYZE SC) HAE Pro

  13. Slide 13: Lifitegrast has potential to be the 1st product to treat Dry Eye Disease

    Lifitegrast has potential to be the 1st product to treat signs and symptoms of Dry Eye Disease (DED) Lifitegrast (SHP606) under FDA review for the treatment of the signs and symptoms of dry eye disease; PDUFA date October 25, 2015 No advisory committee meeting has been scheduled by FDA for the curre

  14. Slide 14: Proposed combination with Baxalta

    Proposed combination with Baxalta

  15. Slide 15: Proposed combination would create the global leader in rare diseases

    Proposed combination would create the global leader in rare diseases with compelling financials and strong outlook The global leader in rare diseases ~$20B in product sales by 2020 (“20x20”) Multiple $1B+ high-value rare diseases franchises with substantial barriers to entry Complementary expertise

  16. Slide 16: Benefits accrue to shareholders of both companies

    Benefits accrue to shareholders of both companies Baxalta shareholders expected to benefit from Immediate significant premium Acceleration and de-risking of Baxalta’s strategy Enhanced growth trajectory Opportunity to participate in a dynamic growth platform Shire shareholders expected to benefit fr

  17. Slide 17: Questions and Answers

    4 Questions and Answers/ |)

  18. Slide 18: Investor relations contacts

    Investor relations contacts International: Sarah Elton-Farr Souheil Salah T: +44 1256 894157 T: +44 1256 894160 E: seltonfarr@shire.com E: ssalah@shire.com North America: Matt Osborne T: +1 781 482 9502 E: mattosborne@shire.com

  19. Slide 19: Non GAAP financial measures

    This presentation contains financial measures not prepared in accordance with US GAAP. These measures are referred to as “Non GAAP” measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effective tax rate on Non GAAP income before income taxes and e

Baxalta — BAML Global Healthcare Conference 2015 on 6ix